Souhami R L, De Elvira M C
Department of Oncology, University College and Middlesex School of Medicine, London, UK.
Lung Cancer. 1994 Mar;10 Suppl 1:S175-85. doi: 10.1016/0169-5002(94)91680-2.
The evidence that increasing the dose intensity of chemotherapy in SCLC improves survival is reviewed. The paucity of randomized trials, the failure to report delivered dose and the methodological problems in presenting dose intensity data, mean that at present no firm conclusions can be drawn about potential survival benefit with increasing intensity of treatment. It seems possible that increases in survival can be obtained with increased intensity of chemotherapy but the degree is likely to be small and the size of randomised trials must therefore be large.
本文综述了增加小细胞肺癌化疗剂量强度可提高生存率的证据。随机试验数量不足、未报告实际给予的剂量以及在呈现剂量强度数据时存在的方法学问题,意味着目前无法就增加治疗强度是否具有潜在生存获益得出明确结论。化疗强度增加似乎有可能提高生存率,但幅度可能较小,因此随机试验的规模必须足够大。